{"entity":{"type":"insider","cik":"0001767388","url":"/insider/0001767388","json_url":"/insider/0001767388.json","name":"F2 Bioscience II 2017 Ltd","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":2,"first":"2019-02-21","last":"2019-12-20","span_basis":"filed_date"},"name_variants":[{"name":"F2 Bioscience II 2017 Ltd","source":"filing","n_filings":2,"first_seen":"2019-02-21","last_seen":"2019-12-20"}],"transactions":[{"id":8725355,"accession":"0000899243-19-029791","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-029791","line_url":"/filing/0000899243-19-029791#line-4","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 - TPO Investments LLC; F2 Capital I 2019, LLC; F2 BBG LLC; Jovan-Embiricos Morana; F2 MG Ltd; Globeways Holdings II Ltd; F2 Capital I 2015 Ltd; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Bioscience II 2017 Ltd","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35323.0,"shares_display":"35,323","price_per_share":16.4714,"price_display":"16.47","price_state":"stated","total_value":581819.2622,"total_display":"581,819.26","shares_owned_after":155986.0,"shares_owned_after_display":"155,986","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-19","filed_date":"2019-12-20","scope":"insider"},{"id":8725352,"accession":"0000899243-19-029791","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-029791","line_url":"/filing/0000899243-19-029791#line-3","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 - TPO Investments LLC; F2 Capital I 2019, LLC; F2 BBG LLC; Jovan-Embiricos Morana; F2 MG Ltd; Globeways Holdings II Ltd; F2 Capital I 2015 Ltd; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Bioscience II 2017 Ltd","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6642.0,"shares_display":"6,642","price_per_share":16.4714,"price_display":"16.47","price_state":"stated","total_value":109403.0388,"total_display":"109,403.04","shares_owned_after":82575.0,"shares_owned_after_display":"82,575","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-19","filed_date":"2019-12-20","scope":"insider"},{"id":8725350,"accession":"0000899243-19-029791","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-029791","line_url":"/filing/0000899243-19-029791#line-2","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 - TPO Investments LLC; F2 Capital I 2019, LLC; F2 BBG LLC; Jovan-Embiricos Morana; F2 MG Ltd; Globeways Holdings II Ltd; F2 Capital I 2015 Ltd; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Bioscience II 2017 Ltd","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2433.0,"shares_display":"2,433","price_per_share":17.006,"price_display":"17.01","price_state":"stated","total_value":41375.598,"total_display":"41,375.60","shares_owned_after":191309.0,"shares_owned_after_display":"191,309","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-18","filed_date":"2019-12-20","scope":"insider"},{"id":8725348,"accession":"0000899243-19-029791","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-029791","line_url":"/filing/0000899243-19-029791#line-1","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 - TPO Investments LLC; F2 Capital I 2019, LLC; F2 BBG LLC; Jovan-Embiricos Morana; F2 MG Ltd; Globeways Holdings II Ltd; F2 Capital I 2015 Ltd; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Bioscience II 2017 Ltd","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":458.0,"shares_display":"458","price_per_share":17.006,"price_display":"17.01","price_state":"stated","total_value":7788.748,"total_display":"7,788.75","shares_owned_after":89217.0,"shares_owned_after_display":"89,217","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-18","filed_date":"2019-12-20","scope":"insider"},{"id":8502390,"accession":"0000899243-19-004404","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-19-004404","line_url":"/filing/0000899243-19-004404#line-9","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings II Ltd; F2 BBG LLC; F2 Bioscience II 2017 Ltd; F2 - TPO Investments LLC; F2 Capital I 2019, LLC; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Capital I 2015 Ltd; F2 MG Ltd; Jovan-Embiricos Morana","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-21","scope":"insider"},{"id":8502385,"accession":"0000899243-19-004404","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-19-004404","line_url":"/filing/0000899243-19-004404#line-8","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings II Ltd; F2 BBG LLC; F2 Bioscience II 2017 Ltd; F2 - TPO Investments LLC; F2 Capital I 2019, LLC; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Capital I 2015 Ltd; F2 MG Ltd; Jovan-Embiricos Morana","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":166667.0,"shares_display":"166,667","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2500005.0,"total_display":"2,500,005.00","shares_owned_after":449207.0,"shares_owned_after_display":"449,207","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-21","scope":"insider"},{"id":8502381,"accession":"0000899243-19-004404","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-19-004404","line_url":"/filing/0000899243-19-004404#line-7","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings II Ltd; F2 BBG LLC; F2 Bioscience II 2017 Ltd; F2 - TPO Investments LLC; F2 Capital I 2019, LLC; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Capital I 2015 Ltd; F2 MG Ltd; Jovan-Embiricos Morana","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":166667.0,"shares_display":"166,667","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2500005.0,"total_display":"2,500,005.00","shares_owned_after":166667.0,"shares_owned_after_display":"166,667","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-21","scope":"insider"},{"id":8502376,"accession":"0000899243-19-004404","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-004404","line_url":"/filing/0000899243-19-004404#line-6","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings II Ltd; F2 BBG LLC; F2 Bioscience II 2017 Ltd; F2 - TPO Investments LLC; F2 Capital I 2019, LLC; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Capital I 2015 Ltd; F2 MG Ltd; Jovan-Embiricos Morana","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":133333.0,"shares_display":"133,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":1999995.0,"total_display":"1,999,995.00","shares_owned_after":536962.0,"shares_owned_after_display":"536,962","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-21","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001750019","name":"TCR2 THERAPEUTICS INC.","url":"/issuer/0001750019","role":"Ten percent owner","n_filings":2,"first_seen":"2019-02-21","last_seen":"2019-12-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001767388","retrieved_at":"2026-08-20T20:28:30+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}